MRCPsychLog in
Back to topics

Read this topic

Basic Neurosciences · Paper A

Mesolimbic dopamine pathway

The idea

Four small groups of dopamine cells, three in the midbrain and one in the hypothalamus, doing four completely different jobs at the far end of their roads. The mesolimbic road runs from the ventral tegmental areaA midbrain structure that is a key source of the brain's dopamine reward pathways.Read more → (VTA) to the nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more → and is the one that flags something as worth pursuing; block it and you take the edge off psychosis, which is why every antipsychotic is built to hit it. But the receptor at the end of that road is chemically identical to the receptor sitting at the end of three other roads — to the cortex, to the striatum, to the pituitary — so a drug that cannot tell the roads apart pays for its psychiatric benefit with side effects that have nothing to do with psychosis at all. Your whole job with this topic is learning to read a vignette for which road is being described, because the exam almost always tests the junction, not the destination.

How it works

  • Mesolimbic pathway, cell bodies in the ventral tegmental areaA midbrain structure that is a key source of the brain's dopamine reward pathways.Read more → (VTA) project to the nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more → and related limbic structures. This is the pathway that assigns motivational weight to a stimulus — not pleasure itself, but how much a stimulus grabs your attention and drives you toward it (its "salience"). You can see why this matters clinically: when this pathway fires too readily, ordinary or even irrelevant stimuli start to feel urgently meaningful, which is the leading account of how a delusionA fixed false belief, held with total conviction, that is not shared by the person's culture and is not changed by evidence against it.Read more → or a hallucinationSeeing, hearing, or otherwise sensing something that is not really there.Read more → gets its emotional force. Blocking D2 receptorsThe main dopamine receptor subtype that antipsychotic drugs block to reduce psychotic symptoms.Read more → here is the part of an antipsychotic's action that actually treats positive symptoms.
  • Mesocortical pathway, the same VTA cell bodies also send a separate branch to the prefrontal cortexThe front part of the brain responsible for planning, judgement and controlling impulses.Read more →, where dopamine supports working memory, motivation and the cognitive control that keeps behaviour organised. In schizophreniaA long-term mental illness involving episodes of psychosis such as hallucinations and delusions.Read more → this pathway is thought to run relatively underactive rather than overactive — the leading model for why negative and cognitive symptoms (apathy, poor concentration) sit alongside psychosis rather than resolving when psychosis does. Because a non-selective antipsychotic blocks D2 here too, it cannot easily distinguish "the overactive pathway I want to calm" from "the underactive one I should leave alone" — which is why blunting and cognitive dulling are a real risk, not just a subjective complaint.
  • Nigrostriatal pathway, a separate cell population in the substantia nigraA deep brain structure rich in dopamine cells whose loss causes Parkinson's disease.Read more → pars compacta projects to the dorsal striatum (caudate and putamen), where it is part of the basal gangliaA group of deep brain structures that help control movement and are affected in Parkinson's disease and by antipsychotic drugs.Read more → circuitry that keeps voluntary movement smooth. This is the pathway that degenerates in Parkinson's disease. Block D2 receptorsThe main dopamine receptor subtype that antipsychotic drugs block to reduce psychotic symptoms.Read more → here with an antipsychotic and you reproduce a drug-induced version of the same movement problem: parkinsonism, acute dystoniaInvoluntary muscle contractions causing abnormal, sometimes painful, postures or movements.Read more →, akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more →, and — with sustained blockade — tardive dyskinesia.
  • Tuberoinfundibular pathway, dopamine released from the arcuate nucleus of the hypothalamusA small brain structure that controls basic functions like hunger, temperature, sleep and hormone release.Read more → travels a very short distance to the pituitary, where its entire job is to sit on lactotroph cells and keep prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → release switched off. This is a brake, not a message — so blocking it does not add a new signal, it simply removes the one holding prolactin down, and prolactin rises as a direct consequence. That is why hyperprolactinaemiaA higher than normal level of the hormone prolactin in the blood.Read more → (galactorrhoea, amenorrhoea, sexual dysfunction, and over time reduced bone density) tracks so closely with how much D2 blockade a drug delivers outside the mesolimbic pathwayA dopamine brain pathway linked to reward and motivation, and to the positive symptoms of psychosis.Read more → it was aimed at.

How to spot it

  • A vignette describing a drug reducing hallucinationsSeeing, hearing, or otherwise sensing things that are not really there.Read more → or delusionsA fixed false belief, held with total conviction, that is not shared by the person's culture and is not changed by evidence against it.Read more → by acting on a pathway from the ventral tegmental areaA midbrain structure that is a key source of the brain's dopamine reward pathways.Read more → to the nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more → is describing the mesolimbic pathwayA dopamine brain pathway linked to reward and motivation, and to the positive symptoms of psychosis.Read more →.
  • A vignette describing apathy, poor concentration or blunted motivation attributed to underactive prefrontal dopamine is describing the mesocortical pathway.
  • A vignette describing parkinsonism, acute dystoniaInvoluntary muscle contractions causing abnormal, sometimes painful, postures or movements.Read more →, akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more → or tardive dyskinesia appearing after starting an antipsychotic is describing nigrostriatal blockade.
  • A vignette describing galactorrhoea, amenorrhoea, sexual dysfunction or a raised prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → level after starting an antipsychotic is describing tuberoinfundibular blockade.
  • A vignette describing dopamine neurons firing to a cue that predicts a reward, rather than to the reward itself, is describing the reward-prediction-error model, not a simple pleasure signal.

Tell it apart

  • Mesolimbic vs mesocortical — mesolimbic dysfunction is modelled as overactive and drives positive symptoms; mesocortical dysfunction is modelled as underactive and drives negative/cognitive symptoms, even though both start from the same VTA cell bodies.
  • Mesolimbic vs nigrostriatal — mesolimbic runs VTA to nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more → and governs motivational salience; nigrostriatal runs substantia nigraA deep brain structure rich in dopamine cells whose loss causes Parkinson's disease.Read more → to dorsal striatum and governs movement, and only the second one degenerates in Parkinson's disease.
  • Mesolimbic vs tuberoinfundibular — mesolimbic blockade is the wanted antipsychotic effect; tuberoinfundibular blockade removes a tonic brake on prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → and is an unwanted side effect, not a parallel therapeutic action.
  • Nigrostriatal vs tuberoinfundibular — nigrostriatal blockade produces movement side effects (parkinsonism, dystoniaInvoluntary muscle contractions causing abnormal, sometimes painful, postures or movements.Read more →, akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more →, tardive dyskinesia); tuberoinfundibular blockade produces an endocrine side effect (hyperprolactinaemiaA higher than normal level of the hormone prolactin in the blood.Read more →) through a completely different downstream organ.
  • Dopamine's role here vs a general "pleasure chemical" story — the reward-prediction-error model holds that dopamine firing tracks the gap between expected and received reward (and grows to fire on the predicting cue itself), which is closer to wanting and anticipation than to the moment-to-moment experience of pleasure.
  • Mesolimbic vs "mesostriatal" — mesostriatal is a genuine term in the dopamine literature, the usual umbrella for midbrain-to-striatum projections (nigrostriatal together with the ventral projection to the accumbens). It is a different carve-up of the same neurons, not one of the four pathways psychiatry teaches, so a stem offering it is testing whether you answer inside the four-pathway scheme the question is built on.

Watch for

  • ⚠️ Assuming any D2-blocking drug can be selective enough to hit only the mesolimbic pathwayA dopamine brain pathway linked to reward and motivation, and to the positive symptoms of psychosis.Read more → — no antipsychotic in routine use achieves that; the side-effect profile you see (heavy on extrapyramidal side effects — EPSE, meaning drug-induced movement problems — or heavy on prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, or neither) reflects how quickly or incompletely a drug leaves D2 receptorsThe main dopamine receptor subtype that antipsychotic drugs block to reduce psychotic symptoms.Read more → elsewhere, not true anatomical selectivity.
  • Treating dopamine as simply "the pleasure chemical" — the prediction-error model fits the exam's favourite trick questions (why does the cue itself trigger firing before any reward arrives) much better than a pure pleasure story does.
  • Forgetting that the mesocortical pathway is hypoactive, not hyperactive, in the standard model — a stem describing negative symptoms is not testing the same direction of dysfunction as one describing hallucinationsSeeing, hearing, or otherwise sensing things that are not really there.Read more →.
  • Confusing nigrostriatal side effects (movement) with tuberoinfundibular side effects (prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →) because both are "unwanted D2 blockade" — they affect completely different organ systems and appear at different points after starting a drug.
  • Reaching for "mesostriatal" because you have genuinely met the word — it is real, but it groups midbrain-to-striatum projections under one heading rather than naming one of the four pathways a psychiatry stem asks you to choose between.

Use it again

  • First ask which organ system the stem's clinical finding belongs to: mental state (mesolimbic/mesocortical), movement (nigrostriatal) or endocrine (tuberoinfundibular) — that alone eliminates two of the four pathways immediately.
  • If the finding is a movement sign, default to nigrostriatal rather than mesolimbic, even though both involve dopamine and both can appear on the same drug chart.
  • If the finding is an endocrine or reproductive symptom, default to tuberoinfundibular and check whether the stem is describing a brake being removed (blockade) rather than a signal being added.
  • When a stem describes a firing pattern shifting from the reward itself to the cue that predicts it, recognise this as the prediction-error model and resist the pull toward a simple "more dopamine equals more pleasure" answer.
  • Before choosing an unfamiliar pathway name, check it against the four this scheme uses: a term like "mesostriatal" can be perfectly real in the literature and still be the wrong answer to a question built on the four-pathway list.

In detail

In this lesson

  1. Hook — one cell, four roads
  2. Plain definition — four roads, named for where they start and end
  3. The critical caveat — a drug cannot choose its destination
  4. First principles — why the same block does four different things
  5. Structured walk-through — the numbers behind the trade-off
  6. Look-alikes & differentials — sorting one drug's effects by organ
  7. Diagnosis — you confirm the consequence, never the pathway
  8. Management — what the pathway model actually changes in practice
  9. Exam pearl — organ system first, pathway name second
  10. In one line — four roads, one drug that cannot read signs

In this lesson

  1. Hook — one cell, four roads
  2. Plain definition — four roads, named for where they start and end
  3. The critical caveat — a drug cannot choose its destination
  4. First principles — why the same block does four different things
  5. Structured walk-through — the numbers behind the trade-off
  6. Look-alikes & differentials — sorting one drug's effects by organ
  7. Diagnosis — you confirm the consequence, never the pathway
  8. Management — what the pathway model actually changes in practice
  9. Exam pearl — organ system first, pathway name second
  10. In one line — four roads, one drug that cannot read signs

Hook — one cell, four roads

Start with a single dopamine-making cell body sitting in your midbrain. It does not send its signal to one place — its axon forks, and the forks travel to at least four genuinely different destinations, each doing a completely different job. A drug that blocks the receptor at the end of one road blocks the identical receptor at the end of all the others, because they are built from the same molecular parts. That single fact — one , one receptor family, four unrelated destinations — is the whole reason antipsychotics both work and cause side effects, and it is the whole reason this topic exists on the exam. By the end of this page you should be able to take any dopamine-related clinical finding and name, confidently, which road it came from.

Plain definition — four roads, named for where they start and end

A dopamine pathway is simply a bundle of dopamine-releasing neurons that all start in roughly the same place and end in roughly the same place. Psychiatry works with four of them: mesolimbic (midbrain to the reward-related ), mesocortical (the same midbrain region to the ), nigrostriatal (a different midbrain nucleus to the movement-related striatum), and tuberoinfundibular ( to pituitary). "Meso-" tells you the road starts in the midbrain; what follows it tells you where the road ends.

The critical caveat — a drug cannot choose its destination

An antipsychotic does not "target" psychosis the way a key fits one lock, and assuming it does is where this topic goes wrong for most people. The drug blocks a receptor subtype (D2), and that same receptor subtype sits at the end of all four roads. The drug has no way of knowing which road it is currently sitting on. So the psychiatric benefit (mesolimbic blockade) and the side effects (nigrostriatal and tuberoinfundibular blockade) are not separate decisions the drug makes — they are the same decision, made simultaneously, four times over, with only the anatomy at each end deciding what actually happens. If you remember nothing else from this page, remember that: one decision, four consequences, decided by anatomy, not by the drug's intentions.

First principles — why the same block does four different things

Work from what each destination was already doing before the drug arrived. Take them one road at a time.

The (the mesolimbic destination) uses dopamine to flag which stimuli are worth your attention and effort — not pleasure exactly, but urgency, the pull to act. In psychosis this circuit is thought to fire too readily, so ordinary events start to feel charged with meaning that is not really there; damping it down with a D2 blocker damps down that false urgency.

The (the mesocortical destination) uses dopamine differently, to support concentration and organised behaviour, and in this pathway is thought to run underactive rather than overactive. So the same drug, hitting the same receptor, calms an overactive circuit in one place while doing nothing helpful — and arguably adding insult — to an already-underactive circuit in another.

The striatum (the nigrostriatal destination) uses dopamine to keep movement smooth by balancing two opposing motor circuits; remove the dopamine brake there and movement becomes stiff, tremulous or restless.

The pituitary (the tuberoinfundibular destination) is the simplest of the four: dopamine's only job there is to sit on -making cells and stop them firing. Block that dopamine and you have not added a new signal — you have removed the only thing holding prolactin down, so it rises on its own.

Structured walk-through — the numbers behind the trade-off

Here is where the trade-off becomes something you can actually put a figure on. PET studies measuring how much of the striatal population a drug occupies produced three thresholds worth committing to memory. Clinical benefit against positive symptoms appears once occupancy reaches about 65%. elevation appears from about 72%. Movement side effects become sharply more likely above about 80%, while the psychiatric benefit beyond that point plateaus rather than improving further.

Those three numbers sit uncomfortably close together, and that is the whole problem: the gap between "working" and "causing trouble" is only about fifteen percentage points wide. It is why dose-finding for antipsychotics is not "more is better" — once past roughly 80% occupancy you are buying side effects rather than extra efficacy, because the mesolimbic benefit has already saturated and you are simply deepening nigrostriatal blockade for no further gain.

Look-alikes & differentials — sorting one drug's effects by organ

Run your own first guess against this table before you commit to an answer.

Looks like a mesolimbic effectHow to tell it apart
Nigrostriatal blockade (tremor, rigidity, , )A movement-system finding, not a mental-state finding — different organ, different timescale
Tuberoinfundibular blockade (galactorrhoea, amenorrhoea, raised )An endocrine finding driven by a brake being removed, not a new signal being sent
Mesocortical hypoactivity (apathy, poor concentration)The opposite direction of dysfunction to mesolimbic overactivity, even though both start from the same cell bodies
"Mesostriatal"A real term, but a different carve-up: it groups every midbrain-to-striatum dopamine projection under one heading instead of naming one of the four pathways this scheme uses

Diagnosis — you confirm the consequence, never the pathway

You cannot image or biopsy "the " in a living patient and confirm it is overactive — that inference is made indirectly, from the clinical picture responding (or not) to D2 blockade, not from a direct pathway-level test. There is no investigation on any request form that returns “mesolimbic overactivity”. What clinicians actually measure directly are the downstream consequences: a level for suspected tuberoinfundibular blockade, and a structured movement examination (for example a rating scale for extrapyramidal signs) for suspected nigrostriatal blockade. Recognising which pathway a finding belongs to is therefore a clinical-reasoning skill, not a diagnostic test.

Management — what the pathway model actually changes in practice

There is no drug that manages "the " alone; management is about minimising the cost of hitting the other three roads while keeping the mesolimbic benefit. NICE's guidance on psychosis and (CG178) is built around exactly this trade-off: start at the lowest effective dose, titrate against response rather than reflexively upward, and monitor specifically for the things the other pathways predict — weight, movement side effects, and — rather than treating antipsychotic prescribing as a single undifferentiated decision. If nigrostriatal or tuberoinfundibular side effects emerge, the practical options (switching to a drug with different receptor kinetics, or adding a short-term for acute ) all follow directly from which pathway is actually causing the problem.

Exam pearl — organ system first, pathway name second

Whenever a vignette hands you a dopamine-related finding, resist naming a pathway from memory before you have asked which organ system the finding sits in. Mental state points to mesolimbic or mesocortical; movement points to nigrostriatal; anything endocrine or reproductive points to tuberoinfundibular. Test yourself here: could you explain to a study partner why one antipsychotic tablet can make a patient's improve, their hands start shaking, and their periods stop — all at once, all correctly, and all through the same receptor?

In one line — four roads, one drug that cannot read signs

Four dopamine roads leave the midbrain and for four different destinations, and a D2-blocking drug cannot tell them apart — so localise every clinical finding by the organ system it affects, not by which pathway you remember best.

Try a question from this area

  • Question 1
  • Question 2
  • Question 3